Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide-Reference-Cited by-同舟云学术

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide

Published:2019-08-22 Issue:5 Volume:28 Page:2229-2238
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Patel Mallika P.,Woodring Sarah,Randazzo Dina M.,Friedman Henry S.,Desjardins Annick,Healy Patrick,Herndon James E.,McSherry Frances,Lipp Eric S.,Miller Elizabeth,Peters Katherine B.,Affronti Mary Lou^ORCID

Funder

Merck

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-019-05039-x.pdf

Reference30 articles.

1. Abdel-Rahman O (2016) Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. Ther Adv Med Oncol 8(5):396–406. https://doi.org/10.1177/1758834016654902

2. Aapro M (2018) Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-concluding thoughts. Support Care Cancer 26(Suppl 1):35–37. https://doi.org/10.1007/s00520-018-4121-5

3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330